Characteristics | Model 1 | Model 2 | Model 3 | Model 4 |
|---|
OR (95% CI) | P | AOR (95% CI) | P | AOR (95% CI) | P | AOR (95% CI) | P |
|---|
Hypouricemia | 3.447 (2.068,5.743) |  < 0.001 | 4.015 (2.262,7.127) |  < 0.001 | 4.174 (2.350,7.414) |  < 0.001 | 4.707 (2.570,8.620) |  < 0.001 |
Normouricemia | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Hyperuricemia | 5.078 (3.222,8.004) |  < 0.001 | 3.133 (1.896,5.179) |  < 0.001 | 3.198 (1.931,5.295) |  < 0.001 | 3.707 (2.174,6.321) |  < 0.001 |
- Model 1: Unadjusted; Model 2: Adjusted for age, gender (male or female), active smoking (yes or no), BMI, hypertension (yes or no), T2DM (yes or no), TC, TG, LDL-C, HDL-C, serum albumin and CKD (yes or no); Model 3: Adjusted for model 2 covariates plus RA disease duration, RF positivity (yes or no), ACPA positivity (yes or no), ESR, CRP, CDAI, HAQ-DI, mTSS; Model 4: Adjusted for model 3 covariates plus previous treatment, including treatment naïve (yes or no), glucocorticoid (yes or no), methotrexate (yes or no), leflunomide (yes or no), hydroxychloroquine (yes or no), sulfasalazine (yes or no), cyclosporine A (yes or no), TNF inhibitors (yes or no), tocilizumab (yes or no), Janus kinase inhibitors (yes or no), statin (yes or no), aspirin (yes or no)
- CVD cardiovascular disease, SUA serum uric acid, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, ESR erythrocyte sedimentation rate, CRP, C-reactive protein, CDAI clinical disease activity index, HAQ-DI health assessment questionnaire disability index, mTSS modified total Sharp score, TNF tumor necrosis factor T2DM type 2 diabetes mellitus, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol; CKD chronic kidney disease, OR odds ratio, AOR adjusted OR; CI confidence interval
